+34 679 490 537info@nanbiosis.com

Posts Taged bioengineering

The importance of Nanomedicine and Bioengineering to address health challenges

Josep Samitier, Coordinator of the Nanomedicine Platform (NanoMed) and Director of IBEC, as well as Scientific Director of NANBIOSIS unit 7 of Nanotecnology, of IBEC and CIBER-BBN, particiated in the XIV Annual Conference of Biomedical Research Technology Platforms was held on 11 and 12 May.

The Conference counted with the presence of relevant public and private sector actors, and more than 700 registered participants. During the opening ceremony, was opened, among others, by the Minister of Science and Innovation, Pedro Duque, it was precisely emphasized the importance of investment in science and technology. In the words of Josep Samitier: “The health area is experiencing a paradigm shift towards predictive, preventive, personalized, participatory, precision medicine and integrated healthcare. This change cannot be achieved without the different medical technologies, with special importance of nanomedicine, which will offer new opportunities to face the challenge by increasing the efficiency of health systems, while reducing costs ”. Samitier also reminded that two of the vaccines currently administered in Spain are based on nanotechnology. 

Source of information: IBEC

Read More

JUMISC, partner of NANBIOSIS, represents Spain in a European network of 22 countries

The Jesús Usón Minimally Invasive Surgery Centre (JUMISC), partner of NANBIOSIS toguether with CIBER-BBN,  leads a multidisciplinary European research network to improve present urinary stents and prevent their causes of failure.

The idea of creating the network was born from a research, started in 1999 by Doctor Soria, Researcher-Coordinator of the Endoscopic Surgery Area at the JUMISC and the promoter of the mentioned network, representing Spain.

His proposal has been supported by the European and Spanish Urology Association, and funded by the Horizon 2020 Program-Cost Actions (European Cooperation in Science and Technology)

The focus of this Action is to create a multidisciplinary team to identify the problems concerning the urinary stents (design, composition, biomaterial applications, coatings, incrustation, etc.) and to promote future research on this field. In this way, the network will try to reduce adverse effects provoked by the present stents.

This European network (2017-2021), coordinated by Dr. Soria, the Chair of the Action, is composed by 22 European countries and other proposals coming from USA,  Japan, South Korea,  Israel, Canada, Russia, India and it is open to other invited countries to cooperate inside  the organised working groups.

This action will provide, during the next 4 years, an extensive and interdisciplinary R&D program to discover the causes of failure of the present stents and will propose cooperative work in urology and bioengineering field.

This proposal, an initiative of the JUMISC, leaded by Doctor Sánchez Margallo, will contribute to improve healthy-quality of patients, reduce in health care costs, and increase the competitiveness of the European medical device industry.

Read More

Bioengineering is being strengthened in Spain

Estefanía Peña, Scientific Coordinator of Unit 13 of NANBIOSIS explains her resarch in the program “En route with science” of Aragon Television.

Bioengineering consists in the application of the principles of engineering to the field of medicine. In the opinion of Estefanía, coordinator of the Division of Biomedical Engineering and deputy director of I3A (Institute of Research in Engineering of Aragon) Bioingineering is being strengthened in Spain.

“Our research develops mathematical models and computational reproduction, especially of cardiovascular diseases and the therapies to solve them. Fundamentally we work on atherosclerosis, which is the appearance and development of atheroma plaque (a cluster of cholesterol in the wall of an artery)

This is a field with a very important social impact (35% of the deaths in Europe are due to cardiovascular diseases and the annual European cost can be around almost two hundred billion euro), this is why we try to reduce the part of experimentation developing mathematical models, both to understand the biological process, and to design new devices as stems.”

For further information:

http://alacarta.aragontelevision.es/programas/en-ruta-con-la-ciencia/ Cap 45 Min.21:42-28:12

Read More